SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:umu-38999"
 

Sökning: onr:"swepub:oai:DiVA.org:umu-38999" > Effects of losartan...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004804naa a2200481 4500
001oai:DiVA.org:umu-38999
003SwePub
008110114s2009 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:118618634
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-389992 URI
0247 a https://doi.org/10.1097/HJH.0b013e32831daf962 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1186186342 URI
040 a (SwePub)umud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Olsen, Michael Hechtu Glostrup University Hospital, Glostrup, Denmark4 aut
2451 0a Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy :b the losartan intervention for endpoint reduction in hypertension (LIFE) study
264 1c 2009
338 a print2 rdacarrier
520 a Objective: Beta-blockers and angiotensin II receptor blockers have different effects on lipids. Methods: We examined lipid levels in the Losartan Intervention For Endpoint reduction in hypertension study and their impact on the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke. We measured total and high-density lipoprotein cholesterol at baseline and annually during 4.8 years of losartan-based compared with atenolol-based treatment in 8611 patients with hypertension and left ventricular hypertrophy. Results: Patients randomized to losartan-based or atenolol-based treatment had similar baseline total (6.04 ± 1.12 vs. 6.05 ± 1.13 mmol/l, NS) and high-density lipoprotein (HDL) cholesterol (1.50 ± 0.44 vs. 1.49 ± 0.44 mmol/l, NS). Total cholesterol decreased significantly but equally (-0.37 ± 1.05 vs. -0.34 ± 1.09 mmol/l, NS), whereas HDL cholesterol decreased less during the first 2 years in patients randomized to losartan compared with atenolol (-0.13 ± 0.24 vs. -0.19 ± 0.25 mmol/l) and remained higher each year (1.38, 1.37, 1.42, 1.47, and 1.48 mmol/l vs. 1.32, 1.30, 1.36, 1.40, and 1.42 mmol/l, all P < 0.001) independent of hydrochlorothiazide or statin treatment. In Cox regression analysis, baseline total cholesterol [hazard ratio (HR) = 1.08 (1.02–1.14) per mmol/l, P < 0.01], HDL cholesterol [HR = 0.56 (0.48–0.66) per mmol/l, P < 0.001], and treatment allocation [HR = 0.86 (0.76–0.98), P < 0.05] predicted composite endpoint independently. Using time-varying analyses, the predictive strength of HDL cholesterol was increased [HR = 0.36 (0.30–0.44) per mmol/l, P < 0.001], whereas that of total cholesterol [HR = 1.03 (0.97–1.09) per mmol/l, NS] and treatment allocation [HR = 0.91 (0.80–1.03), NS] were reduced. Conclusion: Losartan blunted the decrease in HDL cholesterol during antihypertensive treatment in the LIFE study. Higher intreatment HDL cholesterol was associated with fewer composite endpoints and may partly explain the better outcome of losartan-based treatment.
7001 a Wachtell, Kristianu Rigshospitalet, Copenhagen, Denmark4 aut
7001 a Beevers, Garethu City Hospital, Birmingham, UK4 aut
7001 a Dahlöf, Björnu Sahlgrenska University Hospital/Östra, Göteborg, Sweden4 aut
7001 a de Simone, Giovanniu Federico II University of Naples, Naples, Italy4 aut
7001 a Devereux, Richard Bu Weill Cornell Medical College, New York City, New York, USA4 aut
7001 a de Faire, Ulfu Karolinska Institutet4 aut
7001 a Fyhrquist, Freju Helsinki University Central Hospital, Helsinki, Finland4 aut
7001 a Ibsen, Hansu Glostrup University Hospital, Glostrup, Denmark4 aut
7001 a Kjeldsen, Sverre Eu Ullevaal University Hospital, Oslo, Norway4 aut
7001 a Lederballe-Pedersen, Oleu Viborg Hospital, Viborg, Denmark4 aut
7001 a Lindholm, Lars Hu Umeå universitet,Allmänmedicin4 aut0 (Swepub:umu)lali0003
7001 a Lyle, Paulette Au Merck Research Laboratories, North Wales, Pennsylvania, USA4 aut
7001 a Nieminen, Markku Su Helsinki University Central Hospital, Helsinki, Finland4 aut
7001 a Omvik, Peru Haukeland University Hospital, Bergen, Norway4 aut
7001 a Oparil, Suzanneu University of Alabama, Birmingham, Alabama, USA4 aut
7001 a Wedel, Hansu Nordic School of Public Health, Gothenburg, Sweden4 aut
7102 a Glostrup University Hospital, Glostrup, Denmarkb Rigshospitalet, Copenhagen, Denmark4 org
7730 t Journal of Hypertensiong 27:3, s. 567-574q 27:3<567-574x 0263-6352x 1473-5598
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-38999
8564 8u https://doi.org/10.1097/HJH.0b013e32831daf96
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:118618634

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy